HomeIMGN • BMV
add
ImmunoGen Ord Shs
Nakaraang pagsara
$268.50
Sakop ng taon
$268.50 - $268.50
Market cap
8.72B USD
P/E ratio
-
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(USD) | Set 2023info | Y/Y na pagbabago |
---|---|---|
Kita | 113.42M | 637.72% |
Gastos sa pagpapatakbo | 37.74M | 12.26% |
Net na kita | 30.75M | 139.54% |
Net profit margin | 27.11 | 105.36% |
Kita sa bawat share | 0.10 | 132.26% |
EBITDA | 26.38M | 134.26% |
Aktuwal na % ng binabayarang buwis | -3.94% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(USD) | Set 2023info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 605.54M | 95.64% |
Kabuuang asset | 822.10M | 129.13% |
Kabuuang sagutin | 260.50M | 44.09% |
Kabuuang equity | 561.60M | — |
Natitirang share | 266.26M | — |
Presyo para makapag-book | 127.25 | — |
Return on assets | 8.45% | — |
Return on capital | 10.17% | — |
Cash Flow
Net change in cash
(USD) | Set 2023info | Y/Y na pagbabago |
---|---|---|
Net na kita | 30.75M | 139.54% |
Cash mula sa mga operasyon | 2.77M | 104.31% |
Cash mula sa pag-invest | -1.35M | -124.92% |
Cash mula sa financing | 32.13M | 7,056.35% |
Net change in cash | 33.55M | 152.12% |
Malayang cash flow | -2.32M | 91.72% |
Tungkol
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Itinatag
1981
Headquarters
Website
Mga Empleyado
277